A vaccine developed by the University of Oxford to protect people from a deadly virus has been granted support by Europe’s medicines regulator.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy. PolTREG established Immuthera ( in Delaware to expand its prese ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The positive opinion for Zenrelia, or ilunocitinib, opens the way for the product's marketing authorization in the European Union in the next 60 days. The company said it expects to launch Zenrelia ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines ...